Previous close | 45.54 |
Open | 46.58 |
Bid | 43.79 x 100 |
Ask | 44.28 x 100 |
Day's range | 43.01 - 48.51 |
52-week range | 7.10 - 50.78 |
Volume | |
Avg. volume | 1,054,319 |
Market cap | 2.397B |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their...
Vera Therapeutics Inc (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, has reported an insider sale according to a recent SEC filing.
Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino